Frederic Godderis, fractional Chief Strategy Officer at Rejuvenate Biomed, is a biopharmaceutical R&D leader and entrepreneur with extensive drug development, business development and corporate leadership experience. Throughout his career, he has contributed to the development of numerous drugs and established operating models, capabilities, and leadership structures in a variety of large and small biotech and pharma companies. In addition to his role at Rejuvenate Biomed, Frederic is Chief Operating Officer at Tranquis Therapeutics and serves as board director and strategic advisor at several early-stage US based biotech companies. Prior to this, Frederic was co-founder and CEO of LARRK Bio Inc., a clinical stage immuno-dermatology company, and led R&D Operations, Program Leadership, and Program & Portfolio Management functions at Janssen (Johnson & Johnson), Tibotec & Virco, Jazz Pharmaceuticals and Prothena Biosciences. Frederic began his career at Janssen Pharmaceutica in Belgium and worked for several J&J entities across Europe and the US between. Frederic received his MS from the K.U. Leuven university in Belgium.